Skip to main content
NACFC 2025 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Session includes an in person invitee/speaker with CF
Session includes an in person invitee/speaker with CF
Livestreamed Session
Livestreamed Session
Recorded Session
Recorded Session
Session is Ticketed (Must Register for Session through Registration)
Session is Ticketed (Must Register for Session through Registration)
Food Available for Session Attendees
Food Available for Session Attendees

Stephen L. Hart

Department of Genetics and Genomic Medicine, UCL Great Ormond Street Institute of Child Health,London, UK

Stephen Hart, PhD, MSc, BSc, Professor in Molecular Genetics, UCL Great Ormond Street Institute of Child Health

Stephen Hart obtained hs first degree form University of Liverpool in Genetics and went on to obtain an MSc in Human Genetics at the Unviersity of the Witwatersrand, Johannesburg South Africa. He then obtained his PhD from the University of Cape Town. South Africa in 1991. He stated work work in the field of genetic therapies at St Marys Hospital Medical School, London in 1991 and subsequently joined the Institue of Child Health as a postdoc then lecturer in 1994 then professor in 2012. He has more than 100 research publications where his research has focused particularly on the development of non-viral, nanoparticle formulations for nucleic acid delivery to the lung based on nanoformulations of epithelial targeting peptides and lipids.His current research activities include the use of these targeted nanocomplexes for the development and delivery of gene, mRNA and siRNA therapies as well as gene editing for cystic fibrosis. Other target diseases include the respiratory disease primary ciliary dyskinesias, a paediatric cancer, neuroblastoma and neurological conditions. He has held led tow CF Trust Strategic Reseach Centre grant and has held numerous other grants from charities and funding bodies in the UK including the Wellcome Trust, EPSRC and BBSRC, Action Medical Research, Sparks and Worldwide Cancer Research. He is currnetly coinvestigator on both a Lifearc Resepiratory Rare Diseases Research Centre as well as a multinational EU Horizon Marie Curie-Slodowska PhD student fellowship scheme. He is the founder scientist of Nanogenic Solutions Ltd, a UCL spin-out company commercialising nanoparticle formulations for gene and siRNA delivery. He was the chair of the Chemical Gene and Cell Therapy Committee of the American Society of Gene and Cell Therapy (2014-2016) and was a member of the board, elected by the membership in 2018-2021. He is currently a member of the ASGCT’s Respiratory and GI Tract Cell & Gene Therapy Committee.

Presentation(s):